MediBuddy FY25 Financial Highlights
1. Revenue & Income
Operating Revenue: MediBuddy’s revenue from operations grew by 12.3% year-on-year, reaching ₹724.6 crore in FY25, up from ₹645.4 crore in FY24.
Primary Sources: Consultation fees, medicine delivery, lab tests, and insurance services remained the core drivers, accounting for ₹722 crore of the total operating revenue.
Total Income: Including non-operating income (like interest on investments and fixed deposits), the company's total income stood at ₹743 crore.
2. Narrowing Losses
The most significant achievement for MediBuddy in FY25 was the reduction of its net losses:
Net Loss: The company successfully narrowed its losses by 37%, bringing them down to ₹137 crore, compared to ₹215.7 crore in FY24.
EBITDA Margin: Its EBITDA margin improved significantly to -14.19% in FY25 (up from -25.67% in the previous year).
Unit Economics: For every ₹1 of operating revenue earned, the company spent ₹1.21, a noted improvement in operational efficiency.
3. Expense Breakdown
Total expenses for the Bengaluru-based firm remained flat at approximately ₹879 crore.
Material Costs: The largest expense head, accounting for 38% of total spending at ₹333 crore.
Employee Benefits: Increased marginally by 8% to ₹176.8 crore (includes ₹6 crore in ESOPs).
Sales & Commissions: Spending on sales payouts and agent commissions actually declined by 7% to ₹155.47 crore.
Other Costs: The company spent ₹42.5 crore on safety/security and ₹32.5 crore on IT infrastructure.
Market Context & Funding
As of March 2025, MediBuddy maintains a healthy liquidity position with current assets of ₹395.2 crore, including ₹80 crore in cash and bank balances.
The platform has raised approximately $190 million to date. Its last major funding round was an $18 million injection in August 2023 from existing backers like Quadria Capital, Lightrock, and TEAMFund. In the competitive landscape, MediBuddy continues to battle against players like Practo, Tata 1mg, and Lybrate.